Drug Detail

Information about Envafolimab

Generic Name	Envafolimab
IND	KN035
Brand Name (US)
Manufacturer
Drug Type
Delivery	Subcutaneous
Approval Status	Approved in China
Indications
Overall Strategy
Strategy
Drug Category	PD-L1 Antibody

Envafolimab is an anti-PD-L1 nanobody used in cancer immunotherapy.[1] It has been approved in China for the treatment of microsatellite instability-high (MSI-H) or MisMatch Repair deficient (dMMR) solid tumours.[2] Envafolimab (KN035) has obtained the US FDA's orphan drug designation for advanced biliary tract cancer.